The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 09, 2014

Filed:

Mar. 07, 2008
Applicants:

Jose Maria Cid-nunez, Toledo, ES;

Andres Avelino Trabanco-suarez, Olias del Ray, ES;

Gregor James Macdonald, Zoersel, BE;

Guillaume Albert Jacques Duvey, Saint Julien en Genevois, FR;

Inventors:

Jose Maria Cid-Nunez, Toledo, ES;

Andres Avelino Trabanco-Suarez, Olias del Ray, ES;

Gregor James MacDonald, Zoersel, BE;

Guillaume Albert Jacques Duvey, Saint Julien en Genevois, FR;

Assignees:

Janssen Pharmaceuticals, Inc., Titusville, NJ (US);

Addex Pharma, S.A., Geneva, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 405/12 (2006.01); A61K 31/4433 (2006.01);
U.S. Cl.
CPC ...
C07D 405/12 (2013.01);
Abstract

The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) including any stereochemically isomeric form thereof, or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic glutamate receptors subtype 2 ('mGluR2') which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and such compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.


Find Patent Forward Citations

Loading…